Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions ...
Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials
An update from Mineralys Therapeutics, Inc. ( (MLYS) ) is now available. Mineralys Therapeutics announced that the U.S. FDA ...
ETF Daily News16d
Mineralys Therapeutics (NASDAQ:MLYS) Trading Up 4% – Here’s Why
Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) shot up 4% during trading on Friday .The stock traded as high as $13.43 and last traded at $13.39. 9,138 shares were traded ...
Mineralys announces Phase 2 trial of lorundrostat in OSA
Mineralys Therapeutics (MLYS) announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug (IND) ...
Pharmabiz4d
Mineralys Therapeutics gets US FDA nod to begin phase 2 trial of lorundrostat for OSA in patients with hypertension
Radnor, Pennsylvania Friday, January 10, 2025, 18:00 Hrs [IST] ...
Philly’s year in biopharma: a look back at 2024
Iovance Biotherapeutics and Adaptimmune brought first-of-their-kind cell therapy cancer treatments to market. Others had to ...
Yahoo Finance6d
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
RADNOR, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension ...